The U.S. Federal Trade Commission wants more information about the proposed $4 billion tie-up of BTG (LON:BTG) and Boston Scientific (NYSE:BSX), but the companies said they still expect the merger to close on schedule in mid-2019. In a regulatory filing today, Marlborough, Mass.-based Boston Scientific said yesterday’s FTC request “is focused on the beads businesses of Boston Scientific and […]
BTG
BTG touts use of radiopaque drug-eluting bead
BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead. The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG. Get the full story […]
BTG’s bioconvertible IVC filter implanted in Arizona patients
BTG (LSE: BTG) today announced the first successful implantation of its Sentry bioconvertible inferior vena cava (IVC) filter in patients outside of a clinical trial. The Sentry device won FDA 510(k) clearance in 2017. London-based BTG acquired the device in September through its purchase of Galway, Ireland–based Novate. Get the full story on our sister site Medical […]
Boston Scientific offers $4B for BTG
Boston Scientific (NYSE:BSX) said today that it agreed to offer roughly $4.24 billion to acquire British medical device maker BTG (LON:BTG). The £8.40-per-share offer, worth about £3.3 billion, is a 36.6% premium over BTG’s closing price yesterday and a 51.0% premium over the stock’s 90-day volume-weighted average price, the London-based company said. BTG’s largest division makes devices for oncology […]
BTG invests $20m in Veran Medical’s thoracic guidance tech
BTG (LON:BTG) said this week that it invested $20 million in Veran Medical Technologies and its thoracic navigation system. Veran’s thoracic navigation system is designed to help lung specialists diagnose lung cancer earlier, enabling a smooth transition between an endobronchial and transthoracic approach. The technology is also used to localize and mark lung nodules in […]
BTG to pay up to $150M for Irish IVC filter startup
BTG (LSE: BTG) has expanded its pulmonary embolism (PE) business by acquiring Novate Medical Ltd., a startup focused on the prevention of PE in patients at high risk of venous thromboembolic events. Founded in 2006, Novate (Galway, Ireland) develops inferior vena cava (IVC) filters to reduce the likelihood of pulmonary embolism in high-risk clinical situations. Its […]
7 medtech stories we missed this week: June 22, 2018
From Accuray’s India approval to Masimo and PositiveID launching a Bluetooth-enabled thermometer, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. India approves Accuray’s Radixact X9 radiation therapy device Accuray announced in a June 21 press release that it has received an Atomic Energy Regulatory Board Type Approval in […]
FDA panel votes against BTG’s PneumRX Elevair
An FDA advisory committee panel yesterday voted against approving BTG‘s PneumRX’s Elevair endobronchial coil system intended for treating patients with severe emphysema. The panel voted 7 to 5 in favor of the device’s safety, but 8 to 3 that the benefits do not outweigh the risks, and 5 to 7 that the device was effective […]
BTG touts one-year follow-up data for Ekos pulmonary embolism therapy
BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos […]
Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding a […]
BTG to pay $80m for Roxwood Medical
BTG (LON:BTG) said today it will pay up to $80 million to acquire specialized cardiovascular catheter developer Roxwood Medical. In the deal, U.K.-based BTG will pay $65 million upon closure of the deal and an additional $15 million upon the completion of certain future commercial milestones. BTG said it expects the deal to be accretive to […]